Also considered

🎗️ Melanoma — 2026-W36

4 papers judged, 0 emailed  ·  Read the digest →

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Papers judged this week

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Website only
Haybout Lyna et al., J Immunother Cancer

Correlative immune-cytokine biomarker analysis from a phase 1 trial of oncolytic virus TILT-123 plus IL-2-free TIL therapy in checkpoint-inhibitor-resistant metastatic melanoma, published in J Immunother Cancer. Identifies an immune signature associated with survival, offering hypothesis-generating insight but not yet an actionable predictive marker for treatment selection.

Venous thromboembolism and bleeding in advanced melanoma: a propensity-matched cohort analysis comparing first-line immunotherapy and targeted therapy.
Not selected
Bahar Furkan et al., Res Pract Thromb Haemost

Large propensity-matched retrospective cohort study using a federated EHR network, published in Research and Practice in Thrombosis and Haemostasis, comparing thrombotic and bleeding risk between first-line ipilimumab/nivolumab and BRAF/MEK inhibitors in advanced melanoma. Suggests higher VTE risk with combination immunotherapy, which could inform risk counseling and monitoring when choosing between these regimens.

Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors.
Not selected
Tarhini Ahmad A et al., Melanoma Res

Translational analysis of a phase 3 adjuvant ipilimumab melanoma trial, published in Melanoma Research, identifying germline SNPs associated with immune-related dermatitis risk and severity, with dermatitis occurrence linked to improved relapse-free survival. Offers early insight into genetic predictors of ICI skin toxicity but does not yet inform a specific treatment decision.

Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma.
Not selected
Andreoli Mia et al., JCO Oncol Pract

Retrospective single-center cohort study of patients receiving lifileucel TIL therapy for advanced melanoma, published in JCO Oncology Practice. Characterizes outpatient toxicity and readmission after discharge, informing follow-up and monitoring practices for this growing therapy.

← All weeks